Key figures

What does the final I-CARE cohort represent in a few figures ?

For the patients

patient researcher’s actors of this project

patients contacted for the study purposes

eDiaries sent to patients

eDiaries completed by patients

For the investigators

assessable patients

patient – years

of compliance in the ePRO completion

medical reports collected for the coding

of unresolved queries on Annual Summaries

An Annual summary is a recap of data collected along 12 months of follow-up coming from a patient's ePRO questionnaires. It is dedicated to investigators and serves for the control quality of data collection from patient declaration.

We did it !!! Analysis in progress. Thanks to all patients, investigators, partners

31/03/2022 : End of Study for all patients
16/05/2022 : last patient out
17/03/2023 : database lock

508 Participating Investigators
305 Study Nurses
22 contributors (GETAID and external contributors)
15 participating countries

Total included population

Total number of included patients :

13 262

France : 3757
United Kingdom : 2985
Italy : 1051
Greece : 961
Spain : 1026
Belgium : 601
Germany : 560
Denmark : 420

Israel : 465
Ireland : 389
Portugal : 382
Hungary : 317
Netherland : 139
Sweden : 114
Poland : 91

Assessable population (= Patients with at least 2 ePro completed)

Repartition of total number of assessable patients per country (10 206 patients)

Repartition of assessable population per treatment (10206 patients)

Group 1: Patients having never received biological agents or immunosuppressant (all 5-ASA and steroids formulations are permitted) and then (protocol amendment n°7) patients receiving no ongoing immunosuppressant and biologic agent at inclusion in I-CARE study (all previous medication accepted) (all 5-ASA and steroids formulations are permitted)
Group 2: Patients receiving thiopurines alone
Group 3: Patients treated with anti-TNF therapy alone without any concomitant immunosuppressant
Group 4: Patients treated with anti-TNF therapy in combination with thiopurines or methotrexate
Group 5a: Patients treated with vedolizumab alone (without any concomitant immunosuppressant)
Group 5b: Patients treated with vedolizumab in combination with thiopurines or methotrexate.
Group 6: Patients treated with ustekinumab with or without any concomitant medications.